The label expansion theory has a basic problem.
NWBO’s own PR described the MAA as being for DCVax-L for glioblastoma. That is the disclosed application. If the discussion is about label wording within GBM, fine, that is normal review territory. But if the claim is that MHRA may grant a materially broader oncology label beyond the requested GBM indication, that is a much bigger claim.
What evidence supports that?
I am not aware of examples where a regulator simply grants a materially broader oncology label beyond the applicant’s requested indication on its own initiative. Regulators can refine, narrow, or negotiate label wording based on the evidence. But label refinement is not the same thing as a regulator inventing a broader indication the applicant did not request.
If NWBO amended or expanded the MAA to seek a broader label, then where is the disclosure? That would not be a minor detail. It could affect market size, demand, manufacturing burden, reimbursement, commercial planning, and approval timing.
And if the evidence for DCVax-L were so compelling that MHRA might expand the label on its own, then why are we 2.5 years plus into the review with the submitted GBM indication still not approved?
Maybe the answer is manufacturing, CMC, validation, comparability, capacity, labeling, or other unresolved issues. But then that comes back to my point: the delay may reflect unresolved approval issues, not a regulator so impressed that it is quietly expanding the label.
Specials data or real world evidence may or may not be part of the application. But “likely” is not evidence. If the claim is that Specials/RWE supports a broader label, then the questions are: what data, submitted by whom, covering what patient population, showing what outcome, and supporting what exact label?
Without that, the expanded label theory looks more like speculation being used to explain the delay than what MHRA is actually doing.
Market Data 
Markets 
